At-Home Fertility Hormone Patch Global Market Report 2025

The at-home fertility hormone patch market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.59 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. The growth during the historic period can be attributed to rising awareness of infertility and delayed childbearing, the increasing adoption of at-home diagnostic and monitoring devices, capacity constraints and long wait times at fertility clinics, growth in direct-to-consumer telemedicine services, and increased investment in femtech and women’s health startups.

The at-home fertility hormone patch market size is expected to see rapid growth in the next few years. It will grow to $1.05 billion in 2029 at a compound annual growth rate (CAGR) of 15.4%. The growth during the forecast period can be attributed to the expansion of global distribution and direct-to-consumer channels, favorable regulatory pathways and reimbursement policies, increasing awareness of reproductive health, growing acceptance of home-based diagnostics, and rising demand for non-invasive fertility monitoring. Key trends in the forecast period include innovations in wearable hormone monitoring, telehealth integration for fertility counseling, personalized fertility insights through analytics, affordability-focused product development, and advancements in hormone patch technology.

The increasing prevalence of infertility is expected to drive the growth of the at-home fertility hormone patch market. Infertility is defined as the inability to achieve pregnancy after 12 months of regular unprotected intercourse, or difficulties in conceiving or carrying a pregnancy to term. Its prevalence is rising due to delayed childbearing, as more individuals postpone family planning to later reproductive years, when age-related declines in egg quality, ovarian reserve, and sperm parameters reduce conception success rates. The growing burden of infertility boosts demand for at-home fertility hormone testing solutions, as these patches allow convenient, non-invasive monitoring of reproductive hormones, helping individuals track ovulation, identify fertile windows, and make informed reproductive health decisions without frequent clinic visits. For example, in April 2023, the World Health Organization reported that approximately 17.5% of adults globally, or about 1 in 6 people, face infertility, highlighting the urgent need for accessible, high-quality fertility care. The rising prevalence of infertility is therefore driving market growth.

Increasing investment in women's health initiatives is expected to propel the at-home fertility hormone patch market. Women's health initiatives include programs, policies, and campaigns aimed at improving physical, mental, and reproductive health. Investment is increasing due to recognition of historical healthcare disparities, where women's health concerns have often been overlooked, resulting in fragmented services and poor outcomes. Funding in women’s health supports innovations such as at-home fertility hormone patches by promoting research, improving accessibility, and addressing gaps in reproductive healthcare, empowering women to monitor and manage fertility safely at home. For instance, in March 2025, the UK Department of Health and Social Care allocated $32 million (approximately £25 million) between financial years 2023-2024 and 2024-2025 to establish women’s health hubs as a proof of concept. Growing investment in women’s health initiatives is thus driving market growth.

Major companies in the at-home fertility hormone patch market are developing next-generation solutions, including DNA-based wearable patches for real-time, non-invasive hormone tracking. DNA-based wearable patches use DNA-derived sensors to detect hormone levels in interstitial fluid, allowing users to monitor hormonal fluctuations continuously without invasive blood tests, supporting fertility tracking and overall hormonal health. For example, in February 2025, Level Zero Health Inc., a UK biotechnology company, raised $6.9 million in an oversubscribed pre-seed funding round to develop the world’s first continuous hormone monitoring patch. The DNA-based wearable patch measures hormones such as cortisol, progesterone, estrogen, and testosterone in interstitial fluid, providing real-time insights for fertility tracking, hormonal health management, and remote clinical monitoring. This arm-worn, non-invasive device reduces the need for clinic visits and invasive procedures. The company initially targets B2B clinical applications, including fertility clinics and endocrine treatment centers, with plans to expand into consumer-focused wellness markets.

Major players in the at-home fertility hormone patch market are Amneal Pharmaceuticals LLC, LetsGetChecked Limited, Kindbody Inc., Natural Cycles AB, Jolly Healthcare Pvt. Ltd., TMRW Life Sciences Inc., Easy-Healthcare-Corp, Tempdrop Inc., YO Home Test Inc., Hormona AB, FertilityIQ Inc., Inito Inc., myLAB Box Inc., SteadySense Inc., Persperity Health Inc., Muun Health Inc., Béa Fertility Inc., Level Zero Health Inc., Maman Biomedical Inc., Cue Health.

North America was the largest region in the at-home fertility hormone patch market in 2024. The regions covered in at-home fertility hormone patch report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The at-home fertility hormone patch market research report is one of a series of new reports that provides at-home fertility hormone patch market statistics, including at-home fertility hormone patch industry global market size, regional shares, competitors with the at-home fertility hormone patch market share, at-home fertility hormone patch market segments, market trends, and opportunities, and any further data you may need to thrive in the at-home fertility hormone patch industry. This at-home fertility hormone patch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An at-home fertility hormone patch is a wearable device designed to monitor fertility-related hormone levels through the skin. It noninvasively collects biological data and transmits it to a connected platform for analysis. The technology enables convenient tracking of hormonal changes and identification of fertility patterns at home, providing valuable insights into reproductive health and assisting in predicting fertile windows for improved family planning or fertility management.

The primary product types of at-home fertility hormone patches are single-use patches and reusable patches. A single-use patch is a disposable, sterile medical device intended for one-time, single-patient use, offering simple, hygienic, and maintenance-free hormone tracking at home. These patches monitor hormones such as estrogen, progesterone, luteinizing hormone, follicle-stimulating hormone, and others. They are distributed through multiple channels, including online pharmacies, retail pharmacies, supermarkets or hypermarkets, and more. The patches are used for applications such as female and male fertility testing and are utilized by end-users including home care, clinics, hospitals, and others.

The countries covered in the at-home fertility hormone patch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The at-home fertility hormone patch market consists of sales of multi-hormone tracking patches, temperature and hormone combination patches, estrogen delivery patches, progesterone delivery patches, follicle-stimulating hormone (FSH) micro-needle patches, combination hormone therapy patches, smart fertility tracking patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.